In this short Video, Dr. Meteb Al Foheidi from the Department of Oncology at King Saud Bin Abdulaziz University for Health Science – NGHA, Jeddah& the Chairman of board of directors of Saudi Oncology Society, & Dr Mark Verrill from Northern center for cancer care at Freeman hospital, UK discuss the Monarch 2 HR+ HER2- MBC patients’ characteristics and the OS results

In this short Video, Dr. Meteb Al Foheidi from the Department of Oncology at King Saud Bin Abdulaziz University for Health Science – NGHA, Jeddah& the Chairman of board of directors of Saudi Oncology Society, & Dr Mark Verrill from Northern center for cancer care at Freeman hospital, UK discuss the maturity of OS data from Monarch 2 trial in HR+ HER2- MBC patients

In this short Video, Dr. Meteb Al Foheidi from the Department of Oncology at King Saud Bin Abdulaziz University for Health Science – NGHA, Jeddah& the Chairman of board of directors of Saudi Oncology Society, & Dr Mark Verrill from Northern center for cancer care at Freeman hospital, UK discuss the clinical impact of Monarch 2 OS data on the clinical practice

In this short Video, Dr. Meteb Al Foheidi from the Department of Oncology at King Saud Bin Abdulaziz University for Health Science – NGHA, Jeddah& the Chairman of board of directors of Saudi Oncology Society, & Dr Mark Verrill from Northern center for cancer care at Freeman hospital, UK discuss the delay of chemotherapy in the HR+ HER2- MBC patients receiving Abemaciclib plus Fulvestrant

In this short Video, Dr. Meteb Al Foheidi from the Department of Oncology at King Saud Bin Abdulaziz University for Health Science – NGHA, Jeddah& the Chairman of board of directors of Saudi Oncology Society, & Dr Mark Verrill from Northern center for cancer care at Freeman hospital, UK discuss the safety & tolerability of Abemaciclib and patient counseling